All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Real-world effectiveness of MSC-FFM in ruxolitinib-refractory aGvHD
Bookmark this article
⭐GvHD Hub spotlight: Real-world effectiveness of MSC-FFM in RR-aGvHD⭐
Given the poor prognosis of patients with steroid-refractory acute graft-versus-host disease (aGvHD), new treatment options are needed. Bonig et al. from Goethe University, Frankfurt, Germany; Institute Frankfurt, Frankfurt, Germany; University of Washington, Seattle, WA, USA; published an article in the Journal of Translational Medicine discussing the effectiveness and tolerability of salvage treatment with the allogeneic mesenchymal stromal cell-Frankfurt am Main (MSC-FFM) in heavily pre-treated patients with ruxolitinib-refractory aGvHD in real-world clinical settings.
This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Your opinion matters
14 votes - 66 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox